Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176917 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplantation for Hurler
A Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00176917 is a Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 41 participants, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00176917, a Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.
Conditions Studied
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Busulfan, Cyclophosphamide, ATG
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 1999-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176917
The ClinicalTrials.gov registry entry for NCT00176917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (34% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Mucopolysaccharidosis VI appearing as the primary indexed condition, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00176917 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00176917 about?
NCT00176917 is a clinical study titled "Stem Cell Transplantation for Hurler". The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.
What is the current status of trial NCT00176917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 1999-05. Estimated completion is 2010-05.
What conditions does trial NCT00176917 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis VI, Mucopolysaccharidosis I, Mannosidosis, Mucolipidosis Type II (I-cell Disease).
What interventions are being tested in trial NCT00176917?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Busulfan, Cyclophosphamide, ATG (DRUG).
Who is sponsoring clinical trial NCT00176917?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176917 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucopolysaccharidosis VI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ACTIVE NOT RECRUITING · Phase 1
-
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
COMPLETED
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Study of rhASB in Patients With Mucopolysaccharidosis VI
COMPLETED · Phase 3
-
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.